ProFibrix Starts Phase III Trial Of FibroCaps in Hemostasis
LONDON – ProFibrix BV has moved swiftly from Phase II development and treated the first patients in the Phase III trial of its hemostasis product FibroCaps, less than four months after meeting with the FDA to discuss how to proceed.